Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

  • End date
    Aug 31, 2026
  • participants needed
  • sponsor
    Fujian Medical University Union Hospital
Updated on 7 October 2022


To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate

Condition Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment
Treatment Intravenous immunoglobulin
Clinical Study IdentifierNCT05520892
SponsorFujian Medical University Union Hospital
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Subjects enrolled in this study must meet all of the
following criteria
Meet the diagnostic criteria of ITP and be diagnosed for the first time without treatment
Age > 28 days and ≤ 14 years old
Have signed the informed consent

Exclusion Criteria

Anyone who has any of the following conditions will not enter the
clinical study
Intracranial hemorrhage or severe gastrointestinal or urinary tract hemorrhage
requiring emergency treatment, such as simultaneous use of platelet transfusion and
glucocorticoid therapy
Received glucocorticoid or IVIG therapy within 6 months
Weight > 40kg
Menstrual female patients
Patients with underlying diseases such as tumor diseases, autoimmune diseases or
genetic diseases
Patients who have received radiotherapy and chemotherapy
There are any significant abnormal coexisting diseases or mental illnesses that affect
the patient's life safety and compliance, and affect informed consent, research
participation, follow-up or interpretation of results -
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note